Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cann GroupASX:CAN 3-Year EPS without NRI Growth Rate is 22.10% as of Dec. 2025, which is 414% above its 10-year median of 4.30. The stock has 7 warning signs investors should review. Among 786 Drug Manufacturers companies, Cann Group ranks better than 68.83% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 22.10% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 17.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 9 years, the highest 3-Year average EPS without NRI Growth Rate of Cann Group was 22.10% per year. The lowest was -36.70% per year. And the median was 4.30% per year.
Cann Group (ASX:CAN) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Cann Group 3-Year EPS without NRI Growth Rate Related Terms
ASX:CAN vs ZTS: 3-Year EPS without NRI Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cann Group 3-Year EPS without NRI Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cann Group's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Cann Group's 3-Year EPS without NRI Growth Rate falls into.
Cann Group 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 22.10% mean?
Cann Group (ASX:CAN) has a 3-Year EPS without NRI Growth Rate of 22.10% as of Dec. 2025. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Cann Group and its competitors. This is 414% above median its historical median of 4.30. According to the industry distribution chart, Cann Group ranks #245 out of 786 companies in the Drug Manufacturers industry, placing it in the top 31.2%.
Is Cann Group's 3-Year EPS without NRI Growth Rate too high?
Cann Group's current 3-Year EPS without NRI Growth Rate of 22.10% is 414% above median its 10-year median of 4.30. The Drug Manufacturers industry median 3-Year EPS without NRI Growth Rate is 9.60. Cann Group's value of 22.10% is 130.2% above this industry median. Based on the distribution chart, Cann Group ranks #245 out of 786 companies in the Drug Manufacturers industry, which is above the industry midpoint.
How does Cann Group's 3-Year EPS without NRI Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cann Group ranks #245 out of 786 companies for 3-Year EPS without NRI Growth Rate. This puts Cann Group in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 9.60. Cann Group's value of 22.10% is 130.2% above this benchmark. While the company's 10-year median is 4.30 vs. the industry median of 9.60, Cann Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Drug Manufacturers company?
The median 3-Year EPS without NRI Growth Rate among Drug Manufacturers companies is 9.60, based on 786 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cann Group's current 3-Year EPS without NRI Growth Rate of 22.10% is 130.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Cann Group and its competitors. For the Drug Manufacturers industry, the median 3-Year EPS without NRI Growth Rate is 9.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cann Group's current 3-Year EPS without NRI Growth Rate is 22.10%, which is 414% above median its own 10-year median of 4.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cann Group stock overvalued right now?
Based on GuruFocus' analysis, Cann Group (ASX:CAN) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.00 — trading 85% below its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 22.10%, which is 414% above median its 10-year median of 4.30 and 130.2% above the Drug Manufacturers industry median of 9.60. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Cann Group (ASX:CAN), the current 3-Year EPS without NRI Growth Rate is 22.10% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CAN has been successfully added to your 
